Evaluation of Oral Beclomethasone Dipropionate for Prevention of Acute Graft-versus-Host Disease

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 6, 2012, Pages 922-929

  Martin, Paul J ^a,b   Furlong, Terry ^a   Rowley, Scott D ^c   Pergam, Steven A ^a,b   Lloid, Michele ^a   Schubert, Mark M ^a,b   Horgan, Kevin J ^d   Storer, Barry E ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^d Soligenix Inc   (United States)

Author keywords

Acute graft versus host disease; Glucocorticoids; Hematopoietic cell transplantation; Prevention

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; BUSULFAN; CYCLOPHOSPHAMIDE; METHOTREXATE; PLACEBO; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; COLITIS; CONTROLLED STUDY; DIGESTIVE SYSTEM ULCER; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG RELEASE; DRUG SAFETY; DRUG SCREENING; ENTERITIS; ESOPHAGITIS; FEMALE; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL INFECTION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; ILEUS; MAJOR CLINICAL STUDY; MALE; MOUTH INFECTION; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; PATIENT COMPLIANCE; PRESCRIPTION; RANDOMIZED CONTROLLED TRIAL; REFRACTORY ANEMIA; SCHOOL CHILD; STOMACH EROSION; STOMACH ULCER; TYPHLITIS; WHOLE BODY RADIATION;

ACUTE DISEASE; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; BECLOMETHASONE; CHILD; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GASTROINTESTINAL TRACT; GLUCOCORTICOIDS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MUCOSITIS; MYELODYSPLASTIC SYNDROMES; PATIENT COMPLIANCE; PLACEBOS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84860841146     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.11.010     Document Type: Article

References (18)

1. Levine D.S. Immune modulating therapies for idiopathic inflammatory bowel disease. Adv Pharmacol 1994, 25:171-234.
2. Rutgeerts P., Lofberg R., Malchow H., et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994, 331:842-845.
3. Lofberg R., Ostergaard-Thomsen O., Langholz E., et al. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis. Aliment Pharmacol Therapeut 1994, 8:623-629.
4. Martin L.E., Tanner R.J.N., Clark T.J.H., Cochrane G.M. Absorption and metabolism of orally administered beclomethasone dipropionate. Clin Pharmacol Ther 1974, 15:267-275.
5. Oishi T., Deguchi T., Marumo H. Metabolic fate of beclomethasone 17, 21-dipropionate in the rat. Pharmacomet 1981, 22:717-727.
6. Boeckh M., Nichols W.G., Papanicolaou G., Rubin R., Wingard J.R., Zaia J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol Blood Marrow Transplant 2003, 9:543-558.
7. Garcia-Vidal C., Upton A., Kirby K.A., Marr K.A. Epidemiology of invasive mold infections in allogeneic stem cell transplant recipients: biological risk factors for infection according to time after transplantation. Clin Infect Dis 2008, 47:1041-1050.
8. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 1998, 115:28-35.
9. Hockenbery D.M., Cruickshank S., Rodell T.C., et al. A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a prednisone-sparing therapy for gastrointestinal graft-versus-host disease. Blood 2007, 109:4557-4563.
10. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (Prograf®, FK506) with methotrexate and cyclosporine for graft-versus-host prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998, 92:2303-2314.
11. Al-Ghamdi H., Leisenring W., Bensinger W.I., et al. A proposed objective way to assess results of randomized prospective clinical trials with acute graft-versus-host disease as an outcome of interest. Br J Haematol 2001, 113:461-469.
12. Leisenring W.M., Martin P.J., Petersdorf E.W., et al. An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. Blood 2006, 108:749-755.
13. McGuire D.B., Peterson D.E., Muller S., Owen D.C., Slemmons M.F., Schubert M.M. The 20 item oral mucositis index: reliability and validity in bone marrow and stem cell transplant patients. Cancer Invest 2002, 20:893-903.
14. Storb R., Pepe M., Anasetti C., et al. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplantation. Blood 1990, 76:1037-1045.
15. Atkinson K., Biggs J., Concannon A., et al. A prospective randomized trial of cyclosporine and methotrexate versus cyclosporine, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Aust New Zea J Med 1991, 21:850-856.
16. Deeg H.J., Lin D., Leisenring W., et al. Cyclosporine or cyclosporine plus methotrexate for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 1997, 89:3880-3887.
17. Chao N.J., Synder D.S., Jain M., et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind trial. Biol Blood Marrow Transplant 2000, 6:254-261.
18. Ruutu T., Volin L., Parkkali T., Juvonen E., Elonen E. Cyclosporine, methotrexate, and prednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 2000, 96:2391-2398.